FGFR2 (K659N)

FGFR2 · Variant type: point · HGVS: p.K659N

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pemigatinib	100.0%	0.0%	98.23
2	Erdafitinib	99.5%	0.5%	95.71
3	Infigratinib	99.2%	0.8%	98.24
4	Selpercatinib	99.1%	0.9%	96.72
5	Futibatinib	98.7%	1.4%	98.48
6	Alpelisib	98.5%	1.5%	97.22
7	Ponatinib	98.3%	1.8%	78.23
8	Vandetanib	98.1%	1.9%	95.74
9	Nintedanib	98.1%	1.9%	90.23
10	Brigatinib	97.6%	2.4%	82.96
11	Tenalisib	96.6%	3.4%	97.98
12	Deucravacitinib	96.1%	3.9%	98.99
13	Axitinib	93.5%	6.5%	93.23
14	Pralsetinib	93.3%	6.7%	93.43
15	Repotrectinib	93.0%	7.0%	84.21
16	Tivozanib	91.5%	8.5%	92.42
17	Ripretinib	90.7%	9.3%	92.95
18	Canertinib	89.9%	10.1%	96.49
19	Sunitinib	89.4%	10.6%	91.73
20	Entrectinib	86.4%	13.6%	93.69
21	Pazopanib	85.4%	14.6%	97.49
22	Fedratinib	84.4%	15.6%	96.21
23	Erlotinib	84.3%	15.7%	99.75
24	Defactinib	82.5%	17.5%	92.68
25	Dasatinib	82.1%	17.9%	87.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pemigatinib	100.0%	98.7%	+1.3%
Erdafitinib	99.5%	99.0%	+0.5%
Infigratinib	99.2%	98.8%	+0.4%
Selpercatinib	99.1%	95.0%	+4.1%
Futibatinib	98.7%	99.3%	-0.6%
Alpelisib	98.5%	98.9%	-0.4%
Ponatinib	98.3%	99.4%	-1.2%
Vandetanib	98.1%	90.8%	+7.3%
Nintedanib	98.1%	97.0%	+1.1%
Brigatinib	97.6%	96.1%	+1.6%
Tenalisib	96.6%	96.0%	+0.6%
Deucravacitinib	96.1%	92.5%	+3.6%
Axitinib	93.5%	96.1%	-2.7%
Pralsetinib	93.3%	93.2%	+0.1%
Repotrectinib	93.0%	79.8%	+13.2%
Tivozanib	91.5%	—	—
Ripretinib	90.7%	85.4%	+5.3%
Canertinib	89.9%	—	—
Sunitinib	89.4%	—	—
Entrectinib	86.4%	81.5%	+4.9%
Pazopanib	85.4%	88.9%	-3.5%
Fedratinib	84.4%	—	—
Erlotinib	84.3%	—	—
Defactinib	82.5%	—	—
Dasatinib	82.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.4ms